- Home
- MSW vs ESLA Comparison
MSW vs ESLA Comparison
Compare MSW & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSW
- ESLA
- Stock Information
- Founded
- MSW 2012
- ESLA 2021
- Country
- MSW Hong Kong
- ESLA United States
- Employees
- MSW N/A
- ESLA N/A
- Industry
- MSW
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MSW
- ESLA Health Care
- Exchange
- MSW NYSE
- ESLA Nasdaq
- Market Cap
- MSW 37.6M
- ESLA 35.5M
- IPO Year
- MSW 2024
- ESLA N/A
- Fundamental
- Price
- MSW $2.99
- ESLA $0.91
- Analyst Decision
- MSW
- ESLA Strong Buy
- Analyst Count
- MSW 0
- ESLA 1
- Target Price
- MSW N/A
- ESLA $16.00
- AVG Volume (30 Days)
- MSW 287.1K
- ESLA 18.0K
- Earning Date
- MSW 08-25-2025
- ESLA 08-20-2025
- Dividend Yield
- MSW N/A
- ESLA N/A
- EPS Growth
- MSW 18.78
- ESLA N/A
- EPS
- MSW 0.20
- ESLA N/A
- Revenue
- MSW $31,769,612.00
- ESLA N/A
- Revenue This Year
- MSW N/A
- ESLA $101.09
- Revenue Next Year
- MSW N/A
- ESLA N/A
- P/E Ratio
- MSW $14.63
- ESLA N/A
- Revenue Growth
- MSW 30.91
- ESLA N/A
- 52 Week Low
- MSW $1.40
- ESLA $0.63
- 52 Week High
- MSW $10.58
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- MSW N/A
- ESLA 50.86
- Support Level
- MSW N/A
- ESLA $0.83
- Resistance Level
- MSW N/A
- ESLA $0.95
- Average True Range (ATR)
- MSW 0.00
- ESLA 0.07
- MACD
- MSW 0.00
- ESLA 0.01
- Stochastic Oscillator
- MSW 0.00
- ESLA 72.22
About MSW MING SHING GROUP HOLDINGS LIMITED
Ming Shing Group Holdings Ltd is a holding company, which is primarily operated through its indirectly wholly-owned Hong Kong Operating Subsidiaries, MS (HK) Engineering Limited and MS Engineering Co., Limited. It is engaged in wet trades works, such as plastering works, tile laying works, brick laying works, floor screeding works and marble works. the company is mainly engaged in private-sector projects in Hong Kong. Its private sector projects mainly involve private residential developments and commercial developments. The project owners of its private sector projects are generally property developers, and its customers are generally main contractors and wet trades work subcontractors engaged under such projects.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.